a.reyes
TL4 Administrator Co-founder · Governance · Lisbon, PT
Co-founded The Peptide Commons in May 2024 to see whether a peptide community could be run in the open. I write and maintain the guidelines, publish the moderation log, and answer anything about how this place is governed. I am not a clinician and I do not give dosing advice.
Joined 18 May 2024 · last posted 21h · groups: staff, moderators, wiki-editors, trust-level-4
235Posts here
7Topics
1Solutions
1.7kLikes received
1.3kLikes given
37Badges
204Days visited
6.6kPosts read
Stated areas
Recent activity
Full stream-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #100 · Access › Insurance & coverage · 27 Jul 2026 · 3 likes Everything in post #98 holds. The case it does not cover is the one I have. Date every account in this subcategory. Payer criteria change frequently and the archive…
-
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #27 · Analytics › COA interpretation · 27 Jul 2026 · 0 likes I came in to disagree and I am leaving without a disagreement.
-
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one Replied, post #29 · Compounds › Oral incretins · 26 Jul 2026 · 20 likes Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and…
-
Seven-day rolling means and why weekly readings mislead Replied, post #94 · Outcomes › Progress reports · 23 Jul 2026 · 5 likes On post #92 — agreed on the reasoning, with one qualification. I would keep seven-day rolling and the decision it usually gets used for separate in this thread. They…
-
How shortages have affected compounding permissions Replied, post #62 · Access › Shortages · 23 Jul 2026 · 12 likes Adding thanks rather than a view. I do not have a view worth the space.
-
Priming a pen and whether the primed volume is wasted Replied, post #19 · Devices › Pens & autoinjectors · 23 Jul 2026 · 2 likes Pen mechanics: most pens are dial-and-inject devices where you dial the dose on the pen and push the button to inject. Understanding your specific pen's mechanism…
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #50 · Compounds › Secretagogues & GH axis · 23 Jul 2026 · 10 likes This settles it for me, at least until somebody posts a reason it should not.
-
Request: a per-category review queue Replied, post #120 · Meta › Feature requests · 21 Jul 2026 · 0 likes Post #117 is right about the mechanism and I think understates the practical bit. That is exactly the objection, and it is not a refusal on principle. Anything the site…
-
Seven-day rolling means and why weekly readings mislead Replied, post #75 · Outcomes › Progress reports · 21 Jul 2026 · 3 likes Offering a way to settle seven-day rolling rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within…
-
Coming back to: Reconciling a supplier certificate with an independent result Replied, post #28 · Sourcing › Vendor reports · 20 Jul 2026 · 0 likes On Reconciling a supplier certificate, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the…
-
Which categories are strict and which are relaxed, honestly Replied, post #26 · Start Here › Welcome · 18 Jul 2026 · 26 likes Welcome. Two practical notes from staff. Your first few posts are rate-limited, which is an anti-spam measure and not a comment on you, and it lifts on its own. If you…
-
Coming back to: Batch date after test date, and other internal inconsistencies Replied, post #16 · Analytics › COA interpretation · 17 Jul 2026 · 18 likes Narrowing post #15, because the general version has more than one answer. Checked the Batch date claim against the primary source this morning. It survives, with a…
Maintains 3 documents
- Exenatide — referenceReview due 5 Dec 2026
- SURPASS-2 — trial digestReview due 1 Sep 2026
- Cagrilintide plus semaglutide phase 2 — trial digestReview due 16 Nov 2026